Related Experiment Video
Updated: Jun 5, 2026
A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice
Published on: April 17, 2019
[Somatostatin receptor-based imaging and therapy of digestive endocrine tumors]
F Illouz1, J-L Sadoul, V Rohmer
1Département d'Endocrinologie Diabétologie Nutrition, CHU Angers, 4 rue Larrey 49933 Angers cedex 9, France. frillouz@chu-angers.fr
Abstract:
The management of gastroenteropancreatic endocrine tumors is greatly linked to the localization of primary tumor. Morphological imaging methods are thus necessary. However, the expression of somatostatin receptors in endocrine tumors makes their detection possible thanks to radiolabeled somastotatin analogs. [(111)In-DTPA] octreotide is the main radiolabeled analog for somatostatin receptor scintigraphy. Positron emission tomography uses other tracers and currently allows improvement of the diagnosis and the tumoral staging. It also allows to affect the therapeutic management. A further step is about to be taken as far as the therapy of endocrine tumors is concerned with the peptide receptor radionuclide therapy. Those therapies are now being offered in some European and American centers for progressive metastatic tumors. Their place in the therapeutic strategy has to be defined, especially in comparison to targeted therapy. The sudden and delayed adverse events as well as the current legislation on the use of radioactive therapy-aimed products have limited their development in France so far.
Insights
Accurate localization of gastroenteropancreatic endocrine tumors is crucial for management. Radiolabeled somatostatin analogs and advanced imaging like PET improve diagnosis, staging, and therapeutic decisions, including peptide receptor radionuclide therapy.
Area of Science:
- Nuclear medicine
- Oncology
- Endocrinology
Background:
- Gastroenteropancreatic endocrine tumors (GEP-NETs) management relies heavily on primary tumor localization.
- Morphological imaging is essential, but somatostatin receptor expression in GEP-NETs enables detection via radiolabeled somatostatin analogs.
Purpose of the Study:
- To review the role of somatostatin receptor scintigraphy and positron emission tomography (PET) in diagnosing and staging GEP-NETs.
- To discuss the emerging role of peptide receptor radionuclide therapy (PRRT) in managing progressive metastatic GEP-NETs.
Main Methods:
- Utilizes radiolabeled somatostatin analogs, such as [111In-DTPA] octreotide, for scintigraphy.
- Employs positron emission tomography (PET) with specific tracers for improved diagnostic accuracy and staging.
- Considers peptide receptor radionuclide therapy (PRRT) for advanced GEP-NETs.
Main Results:
- Somatostatin receptor scintigraphy with [111In-DTPA] octreotide is a primary diagnostic tool.
- PET imaging enhances diagnosis and tumoral staging, influencing therapeutic management.
- PRRT shows promise for progressive metastatic tumors but requires further strategic definition and faces regulatory hurdles.
Conclusions:
- Advanced imaging techniques, including PET, are vital for GEP-NET diagnosis, staging, and treatment planning.
- PRRT represents a significant advancement in GEP-NET therapy, though its integration into standard treatment strategies is ongoing.
- Adverse events and regulatory considerations currently limit PRRT's widespread adoption in some regions.
